New pill aims to slow Parkinson's progression in early stages
NCT ID NCT06976268
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study tests whether a daily pill called BHV-8000 can slow the worsening of motor skills in people recently diagnosed with Parkinson's disease. About 550 adults aged 40 to 85 with early Parkinson's will receive either BHV-8000 (10 mg or 20 mg) or a placebo for up to 48 weeks. The main goal is to see if the drug delays a meaningful decline in daily living abilities.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
BHV-8000 (a drug taken once daily as a pill)
What this could lead to
If it works, this could point toward a treatment that slows the progression of early Parkinson's disease, helping people stay independent longer.
What could go wrong
This is an early-to-mid-stage trial, so the drug may not prove effective or safe. Results from 550 people may not apply to everyone with Parkinson's.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PARKINSON DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Site-005
RECRUITINGNew York, New York, 10021, United States
-
Site-007
RECRUITINGBellevue, Washington, 98007, United States
-
Site-015
RECRUITINGFarmington Hills, Michigan, 48334, United States
-
Site-017
RECRUITINGBoca Raton, Florida, 33486, United States
-
Site-027
RECRUITINGChicago, Illinois, 60611, United States
-
Site-028
RECRUITINGNew Haven, Connecticut, 06510, United States
-
Site-031
RECRUITINGFarmington, Connecticut, 06030, United States
-
Site-038
RECRUITINGAtlantis, Florida, 33462, United States
-
Site-041
RECRUITINGLos Angeles, California, 90033, United States
-
Site-043
RECRUITINGRound Rock, Texas, 78681, United States
-
Site-044
RECRUITINGChesterfield, Missouri, 63005, United States
-
Site-049
RECRUITINGBirmingham, Alabama, 35294, United States
-
Site-051
RECRUITINGMaitland, Florida, 32751, United States
-
Site-071
RECRUITINGBoston, Massachusetts, 02114, United States
-
Site-091
RECRUITINGPortland, Oregon, 97210, United States